Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;10(8):887-92.
doi: 10.1080/17474124.2016.1209407. Epub 2016 Jul 15.

Apatinib for the treatment of gastric cancer

Giandomenico Roviello  1   2 , Andrea Ravelli  3 , Anna Ida Fiaschi  4 , Maria Rosa Cappelletti  2 , Angela Gobbi  2 , Chiara Senti  2 , Laura Zanotti  2 , Karol Polom  5 , Andrew R Reynolds  6 , Stephen B Fox  7 , Daniele Generali  2   8
Affiliations
Free article
Review

Apatinib for the treatment of gastric cancer

Giandomenico Roviello et al. Expert Rev Gastroenterol Hepatol. 2016 Aug.
Free article

Abstract

Introduction: Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2, has demonstrated encouraging anti-cancer activity in gastric cancer within both in vitro and in vivo models.

Areas covered: Apatinib's efficacy, tolerability and safety have been evaluated in one Phase II and one Phase III study in metastatic/advanced gastric cancer. In this review, we focus on the mechanism of action of apatinib, its pharmacokinetic profile and its clinical activity in the treatment of advanced/metastatic gastric cancer. Expert commentary: Unfortunately, as yet, there is no definitive biomarker data for apatinib in gastric cancer.

Keywords: Gastric cancer; VEGFR2; angiogenesis; apatinib; chemotherapy.

PubMed Disclaimer

MeSH terms